TB-500 is the common name for a synthetic fragment of Thymosin Beta-4, a naturally occurring protein studied for its role in cell migration and tissue-repair signalling in laboratory models. It is sold in the UK strictly for laboratory research use — not for human or veterinary administration.
What is TB-500?
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein found naturally in almost all human and animal cells and at particularly high concentrations in platelets and wound fluid. Tβ4 was first characterised in the 1980s as a thymic hormone, though its actual biological role turned out to be far broader than the endocrine function its name suggests — most of the research interest since has centred on its actin-binding properties and what that means for how cells move.
The "TB-500" designation refers specifically to the synthetic 4-kDa fragment that laboratories use in place of full-length Tβ4, because it is easier to manufacture consistently and is generally considered more stable for research purposes. It is not a trademarked pharmaceutical name — you won't find TB-500 as an approved medicine anywhere, which is an important distinction from compounds that have gone through a regulatory approval pathway.
The proposed mechanism
The research interest in TB-500 stems almost entirely from one property: it binds to G-actin, a building-block protein involved in forming the cytoskeleton that gives cells their structure and lets them move. In cell-culture and animal models, this actin-binding activity has been associated with increased cell migration, and migration is a rate-limiting step in several biological processes researchers care about — new blood vessel formation (angiogenesis), the movement of repair cells to a site of tissue damage, and hair follicle cell migration, among others.
It's worth being precise about what this means: TB-500's proposed mechanism is a cell-biology one, observed largely in vitro and in animal models. It is not a claim about treating any condition in a human being, and none of the published preclinical literature should be read as evidence that it does.
What the published research actually shows
The peer-reviewed literature on Tβ4/TB-500 spans several decades and includes:
- Cell-culture studies demonstrating actin sequestration and its downstream effects on cell motility in various cell lines.
- Animal models of corneal and dermal wound healing, where topical or systemic Tβ4 administration was associated with faster wound closure rates compared to controls.
- Cardiac tissue models in rodents, where Tβ4 has been studied for its potential role in the survival and migration of cardiac progenitor cells following induced injury.
- Angiogenesis assays, examining whether Tβ4-related peptides promote new capillary formation in tissue-culture and animal systems.
Much of this literature is preclinical — meaning it was conducted in cells or animals, not in registered human clinical trials for TB-500 specifically. Some full-length Tβ4 formulations have been trialled in narrow clinical contexts abroad (for example, ophthalmic use), but that is a materially different product and regulatory pathway from the research-grade TB-500 fragment sold for laboratory use, and no such product is licensed for human use in the UK.
Research status and open questions
Reviewers of the Tβ4/TB-500 literature consistently flag the same gaps: dosing and delivery methods vary widely between studies, making cross-study comparison difficult; much of the mechanistic work has not been replicated at scale; and the translation from animal models to any human application remains, at best, an open scientific question rather than an established fact. Anyone using TB-500 in a laboratory setting should treat published claims about its effects with the same scepticism they'd apply to any single-mechanism hypothesis in early-stage peptide research.
UK regulatory status
TB-500 is not an authorised medicine in the UK and carries no marketing authorisation from the UK's medicines regulator. It is legally supplied as a research chemical for laboratory use only, and any UK supplier operating within the law will say so clearly on every product listing — no dosing instructions, no suggestion of a human health benefit, and no marketing that implies it's safe or intended for self-administration.
Sourcing research-grade TB-500 in the UK
For laboratories buying TB-500, the practical questions are the same as for any peptide: is the batch independently tested, is a Certificate of Analysis (COA) available showing purity by HPLC or mass spectrometry, and is the supplier UK-based (which affects both dispatch time and the customs risk that comes with importing research chemicals from overseas). Flex Peptides lists TB-500 with batch-specific COA data available on request, UK dispatch, and the same research-use-only labelling described above — worth checking against whatever supplier you're comparing it to, since COA availability varies a lot across this market.
Key takeaways
- TB-500 is a synthetic fragment of the naturally occurring protein Thymosin Beta-4.
- Its proposed mechanism centres on actin-binding and its effect on cell migration in laboratory models.
- The supporting literature is largely preclinical (cell-culture and animal studies), not human clinical trial data for the fragment itself.
- It has no UK marketing authorisation and is sold strictly for laboratory research.
- COA availability and UK-based dispatch are the two most useful checks when comparing suppliers.
FAQ
Is TB-500 the same as Thymosin Beta-4?
It's a synthetic fragment representing the biologically active region of the full-length protein, not the complete molecule.Is TB-500 legal to buy in the UK?
Yes, as a research chemical for laboratory use, sold with appropriate RUO labelling and no health claims.
This article is for laboratory research information only and does not constitute medical advice. Flex Peptides products are sold for research use only and are not for human or veterinary consumption.
